Abstract:Regulation of therapeutic protein expression by ultrashort peptides. In this engineered mammalian cell system, an ultrashort peptide receptor in the outer membrane detects inducers. Activation of the receptor triggers a signal cascade, leading to expression and secretion of the protein‐of‐interest. Encapsulated cells implanted in mice implement this mechanism, regulating therapeutic protein production, offering targeted treatment for specific diseases. Despite the array of mammalian transgene switches available for regulating therapeutic protein expression in response to small molecules or physical stimuli, issues remain, including cytotoxicity of chemical inducers and limited biocompatibility of physical cues. This study introduces gene switches driven by short peptides comprising eight or fewer amino acid residues. Utilizing a competence regulator (ComR) and sigma factor X‐inducing peptide (XIP) from Streptococcus vestibularis as the receptor and inducer, respectively, this study develops two strategies for a peptide‐activated transgene control system. The first strategy involves fusing ComR with a transactivation domain and utilizes ComR‐dependent synthetic promoters to drive expression of the gene‐of‐interest, activated by XIP, thereby confirming its membrane penetrability and intracellular functionality. The second strategy features an orthogonal synthetic receptor exposing ComR extracellularly (ComREXTRA), greatly increasing sensitivity with exceptional responsiveness to short peptides. In a proof‐of‐concept study, peptides are administered to type‐1 diabetic mice with microencapsulated engineered human cells expressing ComREXTRA for control of insulin expression, restoring normoglycemia. It is envisioned that this system will encourage the development of short peptide drugs and promote the introduction of non‐toxic, orthogonal, and highly biocompatible personalized biopharmaceuticals for gene‐ and cell‐based therapies.

Regulated control of gene therapies by drug-induced splicing

A compact, versatile drug-induced splicing switch system with minimal background expression

A Reversible RNA On-Switch That Controls Gene Expression of AAV-delivered Therapeutics in Vivo

Ultrashort‐Peptide‐Responsive Gene Switches for Regulation of Therapeutic Protein Expression in Mammalian Cells

Engineering Natural Molecule-Triggered Genetic Control Systems for Tunable Gene- and Cell-Based Therapies

A Chemical CRISPR off Switch Efficiently Controls Gene Editing

Small-molecule-based regulation of RNA-delivered circuits in mammalian cells

Orthogonal Control of Endogenous Gene Expression in Mammalian Cells Using Synthetic Ligands

A Gene‐Switch Platform Interfacing with Reactive Oxygen Species Enables Transcription Fine‐Tuning by Soluble and Volatile Pharmacologics and Food Additives

Chemically programed nucleic condensates for spatiotemporal control of mammalian gene expression

Antagonistic Control of a Dual-Input Mammalian Gene Switch by Food Additives.

A tunable, rapid, and precise drug control of protein expression by combining transcriptional and post-translational regulation systems

Control of mammalian gene expression by modulation of polyA signal cleavage at 5′ UTR

Engineered poly(A)-surrogates for translational regulation and therapeutic biocomputation in mammalian cells

Enhancing cell‐based therapies with synthetic gene circuits responsive to molecular stimuli

A Versatile Genetic Control System in Mammalian Cells and Mice Responsive to Clinically Licensed Sodium Ferulate.

Cell‐Specific Control of Mammalian Gene Expression Using DNA Repair Inducible Ribozyme Switches

Protein engineering of gene switches and scissors for human gene therapy

A photo-switchable gold nanoformulation based on the dCas9 protein for spatiotemporal controlled gene editing activation in vivo

Split RNA switch: Programmable and precise control of gene expression by ensemble of pre- and post-translational regulation

Tunable, self-contained gene dosage control via proteolytic cleavage of CRISPR-Cas systems